Evidence map›Paper›PMID 31159170›Full record

ArticleInternational journal of molecular sciences2019

Identification and Characterization of Approved Drugs and Drug-Like Compounds as Covalent

Elisa Sassetti, Cristina Durante Cruz, Päivi Tammela, Mathias Winterhalter, Koen Augustyns, Philip Gribbon, Björn Windshügel

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.3field-weighted citation impact, top 54% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Polydatin as a natural ClpP modulator for combating methicillin-resistantFrontiers in cellular and infection microbiology · 2026
    Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Mutation of the Carboxy-Terminal Processing Protease inPathogens (Basel, Switzerland) · 2020
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 3 countries.

Elisa SassettiFraunhofer Institute for Molecular Biology and Applied Ecology IME, ScreeningPort, 22525 Hamburg, Germany. eli.sassetti@gmail.com.ORCID 0000-0001-9816-5636
Cristina Durante CruzDrug Research Program, Division of Pharmaceutical Biosciences, University of Helsinki, FI-00014 Helsinki, Finland. cristina.durantecruz@helsinki.fi.ORCID 0000-0003-4655-8563
Päivi TammelaDrug Research Program, Division of Pharmaceutical Biosciences, University of Helsinki, FI-00014 Helsinki, Finland. paivi.tammela@helsinki.fi.ORCID 0000-0003-4697-8066
Mathias WinterhalterDepartment of Life Sciences and Chemistry, Jacobs University Bremen gGmbH, 28759 Bremen, Germany. m.winterhalter@jacobs-university.de.ORCID 0000-0002-1604-3318
Koen AugustynsLaboratory of Medicinal Chemistry, University of Antwerp, B-2610 Antwerp, Belgium. koen.augustyns@uantwerpen.be.
Philip GribbonFraunhofer Institute for Molecular Biology and Applied Ecology IME, ScreeningPort, 22525 Hamburg, Germany. philip.gribbon@ime.fraunhofer.de.ORCID 0000-0001-7655-2459
Björn WindshügelFraunhofer Institute for Molecular Biology and Applied Ecology IME, ScreeningPort, 22525 Hamburg, Germany. bjoern.windshuegel@ime.fraunhofer.de.ORCID 0000-0002-4835-3134
University of Helsinki · FIFraunhofer Institute for Molecular Biology and Applied Ecology · DEConstructor University · DEUniversity of Antwerp · BE

Funding

Academy of Finland 277001Academy of Finland 304697H2020 Marie Skłodowska-Curie Actions 642620
6 · The paper itself

Abstract

The serine protease Caseinolytic protease subunit P (ClpP) plays an important role for protein homeostasis in bacteria and contributes to various developmental processes, as well as virulence. Therefore, ClpP is considered as a potential drug target in Gram-positive and Gram-negative bacteria. In this study, we utilized a biochemical assay to screen several small molecule libraries of approved and investigational drugs for

Indexed as

Drug DiscoveryAnti-Bacterial AgentsAntineoplastic AgentsCell Line, TumorCell SurvivalDose-Response Relationship, DrugEndopeptidase ClpEscherichia coli ProteinsHumansInhibitory Concentration 50Molecular Docking SimulationMolecular Dynamics SimulationMolecular StructureProtease InhibitorsProtein BindingProtein ConformationAnti-Bacterial AgentsAntineoplastic AgentsClpP protease, E coliEndopeptidase ClpEscherichia coli ProteinsProtease InhibitorsClpPcovalent bindingEscherichia colihigh-throughput screeninginhibitornitric oxide stresssurface plasmon resonance

Identifiers

PMID31159170
PMCPMC6600665
OpenAlexW2947065846

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.